Gioia Riboni-Verri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gioia Riboni-Verri has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Nick Cunniffe
Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK; Cambridge Clinical Vision Laboratory, University of Cambridge, Cambridge, UK
4 shared publications - Alasdair John Coles
Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
2 shared publications - Christopher E. McMurran
Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
2 shared publications - James William L Brown
Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
2 shared publications Riddhima Gautam
Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
2 shared publicationsAlasdair J Coles
Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
1 shared publication
Latest Publications
- Open Access
- 8 December 2025
- Published by Springer Nature in Trials
- Vol. 26 (1) , 562
The Cambridge Centre for Myelin Repair trial Two (CCMR Two): a trial protocol for a phase 2a, randomised, double-blind, placebo-controlled clinical trial of the ability of the combination of metformin and clemastine to promote remyelination in people with relapsing-remitting multiple sclerosis already on disease-modifying therapy
Background: In multiple sclerosis (MS), progressive disability occurs following degeneration of demyelinated axons. A tractable approach to delay, prevent or reverse disability progression is through enhancement of endogenous remyelination. Clinical trials have deployed drugs, such as clemastine, to target the rate-limiting step in this process: differentiation of oligodendrocyte progenitor cells (OPCs). Preclinical research has shown that metformin can reverse an age-associated deficit in the responsiveness of OPCs to pro-differentiation factors. The purpose of the Cambridge Centre for Myelin Repair trial Two (CCMR Two) is to evaluate the efficacy of the combination of metformin and clemastine to promote remyelination in people with MS. Methods: Participants with relapsing-remitting MS (RRMS) will be randomised 1:1 to the combination of metformin and clemastine or matched placebos and followed for 24 weeks of treatment. All participants must be stable on a disease-modifying therapy and have evidence of chronic stable optic neuropathy in at least one eye (defined by P100 latency of the visual evoked potential (VEP) ≥ 118 ms, and the absence of a history of acute optic neuritis in the preceding 2 years). The primary outcome measure will be the change in the P100 latency of the full-field VEP between baseline and week 26. It is planned to recruit a total of 70 participants. This will have 80% power to detect a reduction of 3 ms in VEP P100 latency between the two treatment groups. Secondary outcome measures will examine the change in multifocal VEP and the change in lesional magnetisation transfer ratio (MTR) for lesions stratified by location and tissue-specific cohort baseline lesional MTR values. Discussion: We set out the trial design, the rationale for participant and outcome measure selection, and the pre-specified analyses. With this trial, we expect to be able to detect the structural and functional consequences of remyelination within a sample size feasible for our single-centre trial. Trial registration: ClinicalTrials.gov NCT05131828, prior to participant enrolment.
- 8 December 2025
- Published by Springer Nature in Trials
- Vol. 26 (1) , 562
Open AccessThe Cambridge Centre for Myelin Repair trial Two (CCMR Two): a trial protocol for a phase 2a, randomised, double-blind, placebo-controlled clinical trial of the ability of the combination of metformin and clemastine to promote remyelination in people with relapsing-remitting multiple sclerosis already on disease-modifying therapy
Background: In multiple sclerosis (MS), progressive disability occurs following degeneration of demyelinated axons. A tractable approach to delay, prevent or reverse disability progression is through enhancement of endogenous remyelination. Clinical trials have deployed drugs, such as clemastine, to target the rate-limiting step in this process: differentiation of oligodendrocyte progenitor cells (OPCs). Preclinical research has shown that metformin can reverse an age-associated deficit in the responsiveness of OPCs to pro-differentiation factors. The purpose of the Cambridge Centre for Myelin Repair trial Two (CCMR Two) is to evaluate the efficacy of the combination of metformin and clemastine to promote remyelination in people with MS. Methods: Participants with relapsing-remitting MS (RRMS) will be randomised 1:1 to the combination of metformin and clemastine or matched placebos and followed for 24 weeks of treatment. All participants must be stable on a disease-modifying therapy and have evidence of chronic stable optic neuropathy in at least one eye (defined by P100 latency of the visual evoked potential (VEP) ≥ 118 ms, and the absence of a history of acute optic neuritis in the preceding 2 years). The primary outcome measure will be the change in the P100 latency of the full-field VEP between baseline and week 26. It is planned to recruit a total of 70 participants. This will have 80% power to detect a reduction of 3 ms in VEP P100 latency between the two treatment groups. Secondary outcome measures will examine the change in multifocal VEP and the change in lesional magnetisation transfer ratio (MTR) for lesions stratified by location and tissue-specific cohort baseline lesional MTR values. Discussion: We set out the trial design, the rationale for participant and outcome measure selection, and the pre-specified analyses. With this trial, we expect to be able to detect the structural and functional consequences of remyelination within a sample size feasible for our single-centre trial. Trial registration: ClinicalTrials.gov NCT05131828, prior to participant enrolment.
- Open Access
- 19 August 2025
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 32 (3) , 347-350
Myelination of the retinal nerve fibre layer: A case report
Background: Aberrant myelination of the retinal nerve fibre layer (RNFL) can follow lamina cribrosa damage. Such cases may provide insight into how increased myelin affects the visual evoked potential (VEP), a key outcome in remyelination trials. Objective: We present the case of a myelinated RNFL in a patient with relapsing-remitting multiple sclerosis (RRMS) with accompanying electrophysiology. Methods: Visual assessments used a VisionSearch Plus, Heidelberg Spectralis optical coherence tomography, and Topcon fundus camera. Results: Full-field visual evoked potential (FF-VEP) peak time latency was abnormally short, 90 ms. Conclusion: This is the first known case report of a myelinated RNFL with electrophysiology, which supports the assertion that reductions in VEP latency correlate with myelination.
- 19 August 2025
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 32 (3) , 347-350
Open AccessMyelination of the retinal nerve fibre layer: A case report
Background: Aberrant myelination of the retinal nerve fibre layer (RNFL) can follow lamina cribrosa damage. Such cases may provide insight into how increased myelin affects the visual evoked potential (VEP), a key outcome in remyelination trials. Objective: We present the case of a myelinated RNFL in a patient with relapsing-remitting multiple sclerosis (RRMS) with accompanying electrophysiology. Methods: Visual assessments used a VisionSearch Plus, Heidelberg Spectralis optical coherence tomography, and Topcon fundus camera. Results: Full-field visual evoked potential (FF-VEP) peak time latency was abnormally short, 90 ms. Conclusion: This is the first known case report of a myelinated RNFL with electrophysiology, which supports the assertion that reductions in VEP latency correlate with myelination.
- Open Access
- 27 July 2025
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 103, 106655
Serum neurofilament light chain levels suggest neuroprotection following bexarotene-induced remyelination in people with relapsing remitting multiple sclerosis
- 27 July 2025
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 103, 106655
Open AccessSerum neurofilament light chain levels suggest neuroprotection following bexarotene-induced remyelination in people with relapsing remitting multiple sclerosis
- Open Access
- 19 February 2024
- Published by BMJ in BMJ Neurology Open
- Vol. 6 (1) , e000560
Visual outcome measures in clinical trials of remyelinating drugs
One of the most promising approaches to delay, prevent or reverse disability progression in multiple sclerosis (MS) is to enhance endogenous remyelination and limit axonal degeneration. In clinical trials of remyelinating drugs, there is a need for reliable, sensitive and clinically relevant outcome measures. The visual pathway, which is frequently affected by MS, provides a unique model system to evaluate remyelination of acute and chronic MS lesions in vivo and non-invasively. In this review, we discuss the different measures that have been used and scrutinise visual outcome measure selection in current and future remyelination trials.
- 19 February 2024
- Published by BMJ in BMJ Neurology Open
- Vol. 6 (1) , e000560
Open AccessVisual outcome measures in clinical trials of remyelinating drugs
One of the most promising approaches to delay, prevent or reverse disability progression in multiple sclerosis (MS) is to enhance endogenous remyelination and limit axonal degeneration. In clinical trials of remyelinating drugs, there is a need for reliable, sensitive and clinically relevant outcome measures. The visual pathway, which is frequently affected by MS, provides a unique model system to evaluate remyelination of acute and chronic MS lesions in vivo and non-invasively. In this review, we discuss the different measures that have been used and scrutinise visual outcome measure selection in current and future remyelination trials.